Biofrontera publishes 1st quarter 2013 interim report
(Thomson Reuters ONE) -
Biofrontera AG /
Biofrontera publishes 1st quarter 2013 interim report
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany, 17 May 2013 - Biofrontera AG (DSE: B8F) has today published
its interim report for the 1(st) quarter 2013 on its corporate webpage.
Since Biofrontera is only obliged to report detailed financial results on a
semi-annual basis, the report shows and comments some relevant key figures and
summarizes the development of the business in the 1(st) quarter of 2013.
The first quarter of 2013 was dominated by the efforts to grow the sales of
Ameluz(®). Ameluz(®) is Biofrontera's prescription drug for the photodynamic
treatment (PDT) of actinic keratosis, a superficial skin cancer. It is marketed
in Germany since February 2012 with Biofrontera's own sales force, and sales in
other European countries started in Q3 2012. Sales had grown strongly the 4(th)
quarter of 2012, and remained rather constant during the 1(st) quarter of 2013,
which is a good result considering the seasonal fluctuations in the use of PDT.
With respect to unit sales, the sales of Ameluz(®) represent about 60% of the
current market with approved PDT-drugs in Germany. However, about 30 times more
treatments of actinic keratosis are performed with legally questionable pharmacy
compounding products or topical drugs with lower efficacy and inferior cosmetic
results. Even though a doubling of the market with approved PDT drugs was
observed in the 1(st) quarter of 2013 compared to previous years, which reflects
a take-over of market share from such treatments, Biofrontera is only at the
very beginning of the development of the Ameluz(®) market. The recent CE-marking
and sales start of Biofrontera's PDT-lamp BF-RhodoLED(®) will support this
process. Biofrontera's revenues in the 1(st) quarter of 2013 were EUR 634,060.
They are solely related to sales in Germany and, to a smaller part, in Austria,
since no manufacturing was done for other countries in this quarter.
The liquidity at the beginning of the year amounted to TEUR 3,366 and to TEUR
8,867 on March 31, 2013. The strong increase in liquidity resulted from a
capital increase in which the strategic investor Maruho Deutschland GmbH bought
9.07% of Biofrontera's share capital. Divers potential collaborations with its
parent company Maruho Co.,Ltd., Osaka, will be explored shortly. The capital
increase provided net proceeds of TEUR 7,475 to Biofrontera.
The cash outflow in the 1(st) quarter amounted to TEUR 2,538. It covers interest
payments of TEUR 436 for the outstanding Biofrontera option bonds and external
research and development costs of TEUR 581. The latter are mostly related to the
clinical trials which have been initiated to achieve the approval of Ameluz(®)
in the USA and extend its approval to the treatment of basal cell carcinoma.
The investment of Maruho and the initiation of the clinical trials for the
approval of Ameluz(®) in the USA represent important milestones in the
international strategic positioning of Biofrontera.
Biofrontera AG
Biofrontera aims at attending and treating the skin, recognizing the aesthetic
needs of a person's visual reflection.Biofrontera AG is listed on the regulated
market of the Frankfurt stock exchange under the symbol B8F and the ISIN number
DE0006046113.
www.biofrontera.com
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forward-
looking statements to reflect future events or developments.
For further information please contact:
Anke zur Mühlen
Corporate Communication
+ 49 (0) 214 87632 22
+ 49 (0) 214 87632 90
a.zurmuehlen(at)biofrontera.com
Biofrontera AG
Hemmelrather Weg 201
D- 51377 Leverkusen, Germany
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1702838]
Unternehmensinformation / Kurzprofil:
Datum: 17.05.2013 - 10:26 Uhr
Sprache: Deutsch
News-ID 261183
Anzahl Zeichen: 5340
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 152 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera publishes 1st quarter 2013 interim report"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
